Order Article Reprints

De Pascale G, Pintaudi G, Lisi L, De Maio F, Cutuli SL, Tanzarella ES, Carelli S, Lombardi G, Cesarano M, Gennenzi V, et al. Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features. Antibiotics. 2023; 12(1):125. https://doi.org/10.3390/antibiotics12010125

De Pascale, Gennaro, Gabriele Pintaudi, Lucia Lisi, Flavio De Maio, Salvatore Lucio Cutuli, Eloisa Sofia Tanzarella, Simone Carelli, Gianmarco Lombardi, Melania Cesarano, Veronica Gennenzi, and et al. 2023. "Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features" Antibiotics 12, no. 1: 125. https://doi.org/10.3390/antibiotics12010125

De Pascale, G., Pintaudi, G., Lisi, L., De Maio, F., Cutuli, S. L., Tanzarella, E. S., Carelli, S., Lombardi, G., Cesarano, M., Gennenzi, V., Ciotti, G. M. P., Grieco, D. L., Posteraro, B., Sanguinetti, M., Navarra, P., & Antonelli, M. (2023). Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features. Antibiotics, 12(1), 125. https://doi.org/10.3390/antibiotics12010125